Current and new pharmacotherapeutic approaches for glaucoma

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
   PubMed Web of Science ®Google Scholar
• Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992;113(4):447–452.
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–20; discussion 829–30. .
   Google Scholar
• Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86–93. .
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953.
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess. 2019;23(31):1–102. DOI:10.3310/hta23310
   Google Scholar
• Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010 Sep 3;4:52–59. DOI:10.2174/1874364101004010052. PMID: 21293732; PMCID: PMC3032230
   Google Scholar
• Addis VM, Miller-Ellis E. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. Clin Ophthalmol. 2018;12:2649–2657.
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Parker L, Birdsong OC, et al. Use of Rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2018;7(3):101–111.
   PubMedGoogle Scholar
• Allergan. Allergan receives FDA approval for durysta™ (bimatoprost implant) the first and only intracameral biodegradable sustained-release implant to lower intraocular pressure in open-angle glaucoma or ocular hypertension patients. 2020 [cited 2020 Mar 5]. Available from: allergan.com/News/Details/2020/03/Allergan%20Receives%20FDA%20Approval%20for%20DURYSTA%20bimatoprost%20implant%20the%20First%20and%20Only%20Intracameral%20Biode
   Google Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514–1517.
   PubMedGoogle Scholar
• Costagliola C, dell’Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother. 2009;10(16):2663–2677.
   PubMed Web of Science ®Google Scholar
• Vidal-Sanz M, Lafuente MP, Mayor-Torroglosa S, et al. Brimonidine’s neuroprotective effects against transient ischaemia-induced retinal ganglion cell death. Eur J Ophthalmol. 2001;11(Suppl 2):S36–40.
   PubMedGoogle Scholar
• European Glaucoma Society Terminology and Guidelines for Glaucoma. 4th edition - Chapter 3: treatment principles and options supported by the EGS foundation. Part 1: foreword; introduction; glossary; Chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195. DOI:10.1136/bjophthalmol-2016-EGSguideline.003
   Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671–681.
   PubMed Web of Science ®Google Scholar
• Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93(3):271–283.
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?–An exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010;29(1):79–93.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Lamparter J, Gericke A, et al. Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res. 2013;353(2):245–251.
   PubMed Web of Science ®Google Scholar
• Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749–760.
   PubMed Web of Science ®Google Scholar
• Tan PP, Yuan HH, Zhu X, et al. Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models. CNS Neurosci Ther. 2014;20(3):227–236.
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009;10(17):2859–2870.
   PubMed Web of Science ®Google Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Holló G. 54 - Carbonic anhydrase inhibitors. In: Shaarawy TM, Sherwood MB, Hitchings RA, editor. Glaucoma. 2nd ed. W.B. Saunders; 2015. p. 559–565.
   Google Scholar
• Kiss B, Dallinger S, Findl O, et al. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am J Physiol. 1999;276(6):R1661–7.
   PubMedGoogle Scholar
• Schallenberg M, Prokosch V, Thanos S. Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma Rat model. PLoS One. 2012;7(7):e33593.
   PubMed Web of Science ®Google Scholar
• Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European glaucoma prevention study. Ophthalmology. 2005;112(3):366–375.
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International dorzolamide study group. Arch Ophthalmol. 1995;113(8):1009–1016.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47(Suppl 1):S53–64.
   PubMed Web of Science ®Google Scholar
• Bhattacherjee P, Paterson CA, Percicot C. Studies on receptor binding and signal transduction pathways of unoprostone isopropyl. J Ocul Pharmacol Ther. 2001;17(5):433–441.
   PubMed Web of Science ®Google Scholar
• Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–456.
   PubMedGoogle Scholar
• Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp Eye Res. 2011;93(3):265–270.
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng P-F, Kumar J, et al. Modulation of aqueous humor outflow facility by the Rho Kinase–specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029–1037.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93(4):e254–60.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288–1295.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–736.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26–34.
   PubMed Web of Science ®Google Scholar
• Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39(8):813–822.
   PubMed Web of Science ®Google Scholar
• Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1–2):52–60.
   PubMed Web of Science ®Google Scholar
• Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2–3):102–109.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Latanoprostene Bunod ophthalmic solution 0.024%: A review in open-angle glaucoma and ocular hypertension. Drugs. 2018;78(7):773–780.
   PubMed Web of Science ®Google Scholar
• Kawase K, Vittitow JL, Weinreb RN, et al. Efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612–1627.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25(10):2543–2547.
   PubMed Web of Science ®Google Scholar
• Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15(12):1737–1747.
   PubMed Web of Science ®Google Scholar
• Machen L, Razeghinejad R, Myers JS. Fixed-combination topical anti-hypertensive ophthalmic agents. Expert Opin Pharmacother. 2020;1–14. DOI:10.1080/14656566.2020.1743264
   PubMed Web of Science ®Google Scholar
• Moosavi R, Ansari E. Brinzolamide/brimonidine fixed combination: simplifying glaucoma treatment regimens. Ophthalmol Ther. 2018;7(2):397–403.
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88(2):199–203.
   PubMed Web of Science ®Google Scholar
• Robin AL. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(4):685–687.
   PubMed Web of Science ®Google Scholar
• Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242–250.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014;15(15):2255–2262.
   PubMed Web of Science ®Google Scholar
• Holló G, Hommer A, Antón López A, et al. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30(6):468–475.
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70–76.
   PubMed Web of Science ®Google Scholar
• Gross RL, Sullivan EK, Wells DT, et al. Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol. 2007;1(3):317–322.
   PubMedGoogle Scholar
• Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• Sheybani A, Scott R, Samuelson TW, et al. Open-angle glaucoma: burden of illness, current therapies, and the management of nocturnal IOP variation. Ophthalmol Ther. 2020;9(1):1–14.
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:4.
   Web of Science ®Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–S6.
   PubMed Web of Science ®Google Scholar
• Blumberg DM, Prager AJ, Liebmann JM, et al. Cost-Related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D. JAMA Ophthalmol. 2015;133(9):985–996.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma. Results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115:8.
   Web of Science ®Google Scholar
• Rossi GCM, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410–414.
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398–2402.
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863–868.
   PubMed Web of Science ®Google Scholar
• Davis SA, Sleath B, Carpenter DM, et al. Drop instillation and glaucoma. Curr Opin Ophthalmol. 2018;29(2):171–177.
   PubMed Web of Science ®Google Scholar
• Kass MA. The ocular hypertension treatment study. J Glaucoma. 1994;3(2):97–100.
   PubMedGoogle Scholar
• Hennessy AL, Katz J, Covert D, et al. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 2010;117(12):2345–2352.
   PubMed Web of Science ®Google Scholar
• Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74(8):477–480.
   PubMed Web of Science ®Google Scholar
• Tsai T, Robin AL, Smith JP. An evaluation of how glaucoma patients use topical medications: A pilot study. Trans Am Ophthalmol Soc. 2007;105:29–33.
   PubMedGoogle Scholar
• Geyer O, Bottone EJ, Podos SM, et al. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79(4):376–379.
   PubMed Web of Science ®Google Scholar
• Schein OD, Hibberd PL, Starck T, et al. Microbial contamination of in-use ocular medications. Arch Ophthalmol. 1992;110(1):82–85.
   PubMedGoogle Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431–436.
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M, Wagner TH. Cost-related medication underuse. Arch Intern Med. 2004;164(16):1749.
   PubMed Web of Science ®Google Scholar
• Gooch N, Molokhia SA, Condie R, et al. Ocular drug delivery for glaucoma management. Pharmaceutics. 2012;4(1):197–211.
   PubMedGoogle Scholar
• Kim SH, Lee EJ, Han JC, et al. The effect of diurnal fluctuation in intraocular pressure on the evaluation of risk factors of progression in normal tension glaucoma. PLoS One. 2016;11(10):1–14.
   Web of Science ®Google Scholar
• Whitson JT. Glaucoma: A review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007;8(18):3237–3249.
   PubMed Web of Science ®Google Scholar
• Yadav KS, Rajpurohit R, Glaucoma: SS. Current treatment and impact of advanced drug delivery systems. Life Sci. 2019;221(December2018):362–376.
   PubMedGoogle Scholar
• Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556–563.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334.
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1454.
   PubMedGoogle Scholar
• Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497.
   PubMedGoogle Scholar
• Brandt JD, Sall K, DuBiner H, et al., Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 123(8): 1685–1694. 2016.
   PubMed Web of Science ®Google Scholar
• Leahy CD, Gutner R, Varney W, et al. Continuous wear non-invasive device for sustained ocular drug delivery. Invest Ophthalmol Vis Sci. 2014;55(13):481.
   Web of Science ®Google Scholar
• Crawford K, Ellis J, Rulander J, et al. Sustained delivery of prostaglandin from drug-containing depots using ocular rings in beagles. Invest Ophthalmol Vis Sci. 2013;54(15):5073.
   Web of Science ®Google Scholar
• Amorphex Theraputics. What differentiates TODDD™ from other sustained delivery technologies in development? 2017-2018. Available from: https://www.amorphexusa.com/development
   Google Scholar
• Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016;123(10):2085–2092.
   PubMed Web of Science ®Google Scholar
• Ocular Therapeutix. OTX-TP (travoprost insert). 2020. Available from: https://www.ocutx.com/research/otx-tp/.
   Google Scholar
• Mati Therapeutics Inc. Evolute® Punctal plug delivery system. 2019.
   Google Scholar
• Fedorchak MV, Conner IP, Schuman JS, et al. Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci Rep. 2017;7(1):8639.
   PubMedGoogle Scholar
• Chiang B, Kim YC, Doty AC, et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J Control Release. 2016;228:48–57.
   PubMed Web of Science ®Google Scholar
• Graybug Vision. Graybug vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American glaucoma society annual meeting. 2020 [cited 2020 Feb 28]. Available from: https://graybug.com/graybug-vision-presents-preclinical-results-for-gb-401-ags/
   Google Scholar
• Icon Bioscience. Verisome drug delivery technology. 2015 [cited 2020 Jun 8]. Available from: https://ois.net/icon-bioscience/
   Google Scholar
• EyePoint Pharmaceuticals. DurasertTM technology. 2018. Available from: https://eyepointpharma.com/our-technology/#durasert
   Google Scholar
• EyePoint Pharmaceuticals. pSivida out-licenses EMEA rights for Durasert™ Three-year treatment for posterior segment uveitis while retaining U.S. Commercial rights; Amended global collaboration agreement with Alimera for ILUVIEN® improves pSivida’s revenue generation 2017 July 10 [cited 2017 July 10]. Available from: http://investors.eyepointpharma.com/news-releases/news-release-details/psivida-out-licenses-emea-rights-duraserttm-three-year-treatment
   Google Scholar
• Gutierrez-Hernandez JC, Caffey S, Abdallah W, et al. One-year feasibility study of replenish MicroPump for intravitreal drug delivery: a pilot study. Trans Vision Sci Technol. 2014;3(4):8.
   PubMed Web of Science ®Google Scholar
• Craven ER, Walters T, Christie WC, et al., 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 80(2): 167–179. 2020.
   PubMed Web of Science ®Google Scholar
• Glaukos. Glaukos corporation’s idose™ travoprost achieves sustained IOP reduction and favorable safety profile in 12-month interim cohort 2018. [cited 2018 Jan 10]. Available from: http://investors.glaukos.com/investors/press-releases/press-release-details/2018/Glaukos-Corporations-iDose-Travoprost-Achieves-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-in-12-Month-Interim-Cohort/default.aspx.
   Google Scholar
• Glaukos C Randomized study comparing two models of a travoprost intraocular implant to timolol maleate ophthalmic solution, 0.5%. 2021 [cited 2018 Mar 8]. Available from: https://ClinicalTrials.gov/show/NCT03519386
   Google Scholar
• Envisia Therapeutics. Envisia therapeutics releases interim env515 (travoprost XR) phase 2 data demonstrating 11-month duration-of-action after a single dose in patients with glaucoma. 2017 Feb 3 [cited 2017 Feb 3]. Available from: http://www.pappas-capital.com/envisia-therapeutics-releases-interim-env515-travoprost-xr-phase-2-data-demonstrating-11-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma/.
   Google Scholar
• Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci. 2013;54(7):4782–4790.
   PubMed Web of Science ®Google Scholar
• Kalouche G, Beguier F, Bakria M, et al. Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2016;57(4):1816–1825.
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health Clinical Trials. A phase III study assessing the efficacy and safety of DE-117 ophthalmic solution compared with timolol maleate ophthalmic solution 0.5% in subjects with glaucoma or ocular hypertension - spectrum 3 study. [cited 2019 Dec 16]. Available from: https://ClinicalTrials.gov/show/NCT03691649
   Google Scholar
• Ihekoromadu N, Lu F, Iwamura R, et al. Safety and efficacy of DE-117, a selective EP2 agonist in a phase 2a study. Invest Ophthalmol Vis Sci. 2015;56(7):5708.
   Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475–1487.
   PubMed Web of Science ®Google Scholar
• Miller Ellis E, Berlin MS, Ward CL, et al., Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study. Br J Ophthalmol. 101(6): 796–800. 2017.
   PubMed Web of Science ®Google Scholar
• Martinez T, Gonzalez MV, Roehl I, et al. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014;22(1):81–91.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Moreno-Montanes J, Oll M, et al., Results of phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Invest Ophthalmol Vis Sci. 57(12): 3023. 2016.
   Google Scholar
• Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther. 1995;273(1):320–326.
   PubMed Web of Science ®Google Scholar
• Tian B, Gabelt BT, Crosson CE, et al. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997;64(6):979–989.
   PubMed Web of Science ®Google Scholar
• Avila MY, Stone RA, Civan MM. A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol. 2001;134(2):241–245.
   PubMed Web of Science ®Google Scholar
• Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002;43(9):3016–3020.
   PubMed Web of Science ®Google Scholar
• Laties A, Rich CC, Stoltz R, et al. A randomized phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics of trabodenoson in healthy adult volunteers. J Ocul Pharmacol Ther. 2016;32(8):548–554.
   PubMed Web of Science ®Google Scholar
• Myers JS, Sall KN, DuBiner H, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2016;32(8):555–562.
   PubMed Web of Science ®Google Scholar
• P&T Community. Glaucoma drug trabodenoson fails phase 3 test: treatment no better than placebo at some time points. 2017 [cited 2017 Jan 3]. Available from: https://www.ptcommunity.com/news/20170103/glaucoma-drug-trabodenoson-fails-phase-3-test
   Google Scholar
• Business Wire. Inotek pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update. 2017 [cited 2017 July 10]. Available from: https://www.businesswire.com/news/home/20170707005601/en/Inotek-Pharmaceuticals-Announces-Top-line-Results-Phase-2
   Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al., The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 122(7): 1308–1316. 2015.
   PubMed Web of Science ®Google Scholar
• Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903–913.
   PubMedGoogle Scholar
• Watson PG, Barnett MF, Parker V, et al. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 2001;85(8):962–968.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Pinheiro A, Moura FC, et al. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther. 2002;18(6):489–498.
   PubMed Web of Science ®Google Scholar